No profile data available.
Carisma Therapeutics, Inc. (CARM) is a healthcare company in the additional cancer treatment drugs industry, based in Philadelphia, United States, with about 46 full-time employees.
It reported revenue of $19.63 million for fiscal year 2024, up 31.6% from fiscal year 2023, and net income of -$60.48 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $45.25 million, up 1236.8% from a year before. Its market capitalization was $2.03 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of December 4, 2025.
, a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidate includes CT-2401, which is in preclinical trail for the treatment of liver fibrosis.
Carisma Therapeutics reported $19.63 million in revenue for fiscal year 2024, up 31.6% from $14.92 million in fiscal year 2023. In Q3 2025 revenue was $45.25 million.
$2.03 million as of December 4, 2025.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include BioAtla, Inc. (BCAB), Genprex, Inc. (GNPX), Purple Biotech Ltd (PPBT), Curis, Inc. (CRIS).